Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
According to the FDA's press release it agreed to approve the drug for obesity based on three randomised, double-blind, placebo-controlled trials during which more than 2,600 patients received Wegovy for up to 68 weeks and more than 1,500 patients received placebo (US FDA 2021)
How Much of the Industry Rides on This Compound No compound touches more clinic menus than this one
Similarly, the STEP 5 trial demonstrated even greater results, with participants achieving a mean weight loss of -15.2% after two years (104 weeks)
The concentrations used in GHK-Cu applications are well below toxic thresholds, but individuals with Wilson's disease (a copper metabolism disorder) should avoid GHK-Cu without physician supervision
